Royalty Pharma (RPRX) Competitors

Royalty Pharma (NASDAQ:RPRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Does the media prefer RPRX or JAZZ?

In the previous week, Royalty Pharma had 19 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 21 mentions for Royalty Pharma and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.27 beat Royalty Pharma's score of 0.91 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Royalty Pharma	Positive
Jazz Pharmaceuticals	Positive

Do analysts rate RPRX or JAZZ?

Royalty Pharma currently has a consensus target price of $41.67, suggesting a potential upside of 38.75%. Jazz Pharmaceuticals has a consensus target price of $177.00, suggesting a potential upside of 43.95%. Given Jazz Pharmaceuticals' higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87

Does the MarketBeat Community prefer RPRX or JAZZ?

Jazz Pharmaceuticals received 801 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 80.76% of users gave Jazz Pharmaceuticals an outperform vote while only 67.92% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Royalty Pharma	Outperform Votes 324 67.92%	Underperform Votes 153 32.08%
Jazz Pharmaceuticals	Outperform Votes 1125 80.76%	Underperform Votes 268 19.24%

Which has preferable valuation and earnings, RPRX or JAZZ?

Royalty Pharma has higher earnings, but lower revenue than Jazz Pharmaceuticals. Royalty Pharma is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.27B	7.81	$1.13B	$1.93	15.56
Jazz Pharmaceuticals	$3.99B	1.86	$414.83M	$7.10	17.32

Do institutionals & insiders hold more shares of RPRX or JAZZ?

54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more volatility and risk, RPRX or JAZZ?

Royalty Pharma has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Is RPRX or JAZZ more profitable?

Royalty Pharma has a net margin of 50.53% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	50.53%	24.65%	14.44%
Jazz Pharmaceuticals	11.60%	29.30%	9.72%

Summary

Jazz Pharmaceuticals beats Royalty Pharma on 11 of the 19 factors compared between the two stocks.